Skip to main content

Chronic Idiopathic Constipation

5
Pipeline Programs
9
Companies
14
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
4100%
+ 11 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
1
1
plecanatidePhase 3Peptide2 trials
SP-304 0.3 mgPhase 21 trial
Active Trials
NCT01053962Completed84Est. Aug 2010
NCT03551873Completed7Est. Dec 2018
NCT02706483Completed2,272Est. Jun 2017
Dr. Reddy's Laboratories
1 program
1
LubiprostonePhase 31 trial
Active Trials
NCT01674530Completed909Est. Mar 2014
Syneos Health
Syneos HealthNC - Morrisville
1 program
1
PlecanatidePhase 3Peptide1 trial
Active Trials
NCT01919697Completed2,370Est. Mar 2016
Kissei Pharmaceutical
Kissei PharmaceuticalJapan - Matsumoto City
1 program
1
KWA-0711Phase 21 trial
Active Trials
NCT01600001Completed75
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
4 programs
elobixibatPHASE_21 trial
Elobixibat 10 mgPHASE_31 trial
Elobixibat 10 mgPHASE_31 trial
Elobixibat 10 mg/dayPHASE_31 trial
Active Trials
NCT02392546Withdrawn0Est. Apr 2016
NCT01895543Completed411Est. May 2015
NCT01827592Terminated376Est. May 2014
+1 more trials
Takeda
TakedaTOKYO, Japan
2 programs
LubiprostonePHASE_2_31 trial
lubiprostonePHASE_41 trial
Active Trials
NCT01469819Completed37Est. Feb 2015
NCT01460225Completed19Est. Jan 2011
Parexel
ParexelMA - Boston
2 programs
plecanatidePHASE_2_3Peptide
LubiprostonePHASE_3
SK Life Science
SK Life ScienceNJ - Paramus
1 program
YKP10811PHASE_21 trial
Active Trials
NCT01989234Completed334Est. Dec 2014
Ironwood Pharmaceuticals
1 program
LinaclotidePHASE_3Peptide1 trial
Active Trials
NCT02291679Completed1,223Est. Aug 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Takedalubiprostone
Bausch Healthplecanatide
Ironwood PharmaceuticalsLinaclotide
Ferring PharmaceuticalsElobixibat 10 mg
Syneos HealthPlecanatide
Ferring PharmaceuticalsElobixibat 10 mg/day
Ferring PharmaceuticalsElobixibat 10 mg
Dr. Reddy's LaboratoriesLubiprostone
TakedaLubiprostone
Ferring Pharmaceuticalselobixibat
SK Life ScienceYKP10811
Bausch HealthSP-304 0.3 mg
Bausch Healthplecanatide

Clinical Trials (14)

Total enrollment: 8,431 patients across 14 trials

NCT01460225Takedalubiprostone

Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation

Start: Sep 2007Est. completion: Jan 201119 patients
Phase 4Completed
NCT02706483Bausch Healthplecanatide

Long Term Safety Study of Plecanatide

Start: Jan 2016Est. completion: Jun 20172,272 patients
Phase 3Completed
NCT02291679Ironwood PharmaceuticalsLinaclotide

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

Start: Oct 2014Est. completion: Aug 20151,223 patients
Phase 3Completed
NCT01895543Ferring PharmaceuticalsElobixibat 10 mg

Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation

Start: Sep 2013Est. completion: May 2015411 patients
Phase 3Completed
NCT01919697Syneos HealthPlecanatide

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Start: Aug 2013Est. completion: Mar 20162,370 patients
Phase 3Completed
NCT01833065Ferring PharmaceuticalsElobixibat 10 mg/day

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

Start: Apr 2013Est. completion: Apr 2014314 patients
Phase 3Terminated
NCT01827592Ferring PharmaceuticalsElobixibat 10 mg

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Start: Apr 2013Est. completion: May 2014376 patients
Phase 3Terminated
NCT01674530Dr. Reddy's LaboratoriesLubiprostone

Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation

Start: Oct 2012Est. completion: Mar 2014909 patients
Phase 3Completed
NCT01469819TakedaLubiprostone

Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation

Start: Jun 2012Est. completion: Feb 201537 patients
Phase 2/3Completed
NCT01600001Kissei PharmaceuticalKWA-0711

A Exploratory Study of KWA-0711 in Patients With Chronic Idiopathic Constipation (CIC)

75 patients
Phase 2Completed
NCT02392546Ferring Pharmaceuticalselobixibat

Elobixibat Colonic Motor Function Study

Start: Apr 2015Est. completion: Apr 20160
Phase 2Withdrawn
NCT01989234SK Life ScienceYKP10811

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation

Start: Oct 2013Est. completion: Dec 2014334 patients
Phase 2Completed
NCT01053962Bausch HealthSP-304 0.3 mg

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

Start: Mar 2010Est. completion: Aug 201084 patients
Phase 2Completed
NCT03551873Bausch Healthplecanatide

A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®

Start: Jun 2018Est. completion: Dec 20187 patients
N/ACompleted

Related Jobs

OT Automation Lead

Ferring PharmaceuticalsFerring Pharmaceuticals
Buenos Aires, Argentina
2w ago

Head of Centre of Expertise Aseptic Processes & Global Technical Operations- Manufacturing Technology & Science

Ferring PharmaceuticalsFerring Pharmaceuticals
Kiel, Germany
2w ago

GXP System and Process Manager

Ferring PharmaceuticalsFerring Pharmaceuticals
Lisbon, Portugal
3w ago

Regulatory Coordinator- (Temporary, Maternity cover)

Ferring PharmaceuticalsFerring Pharmaceuticals
Amman, Jordan
3w ago

MTS Digital & AI Product owner

Ferring PharmaceuticalsFerring Pharmaceuticals
Lisbon, Portugal
3w ago

Global Rewards Operations Senior Analyst

Ferring PharmaceuticalsFerring Pharmaceuticals
Lisbon, Portugal
3w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.